Healthcare ❯ Pharmaceuticals ❯ Drug Development

Regulatory Affairs

FDA Submissions D-PLEX100 FDA Approvals Public Health FDA Regulations

PolyPid Nears Completion of Rolling FDA Filing for D‑PLEX100

Fast‑track status could shorten review to speed the infection‑prevention drug toward hospitals.

Regeneron Tops Q1 Estimates as Dupixent and Libtayo Outpace Eylea

Corcept Investors Pressed to Seek Lead Role in Securities Suit After FDA Rebuff of Relacorilant